Research

Hormonal

Tirzepatide produces significantly greater weight loss than semaglutide in adults with obesity or overweight, with the magnitude of loss increasing with higher doses (>10 mg) and longer treatment durations (>6 months).

If you are using semaglutide and not achieving your weight loss goals, switching to tirzepatide (particularly at doses above 10 mg and continuing for more than 6 months) is likely to result in significantly greater weight loss. The data supports tirzepatide as a more potent option for reducing body weight compared to semaglutide.

GoodSupportsHIGH confidence
MA results showed that compared with the semaglutide, tirzepatide could produce significantly greater weight loss (MD = 4.23; 95% confidence interval (CI): 3.22 - 5.25; P < 0.01). Subgroup analysis showed a dose- and duration-dependent significantly superior therapeutic effect of tirzepatide (> 10 mg dose: MD = 6.50... vs. ≤ 10 mg: MD = 3.89... > 6 months duration: MD = 5.00... vs. ≤ 6 months: MD = 3.50...)
Ahmad Bin Aamir et al. · Journal of Clinical Medicine Research · 2025

Why this rating

High-quality systematic review and meta-analysis including RCTs and real-world retrospective cohorts with low risk of bias, though substantial heterogeneity exists.

Source

Comparative Efficacy of Tirzepatide vs. Semaglutide in Reducing Body Weight in Humans: A Systematic Review and Meta-Analysis of Clinical Trials and Real-World Data

Ahmad Bin Aamir et al. · Journal of Clinical Medicine Research · 2025

DOI 10.14740/jocmr6231

Meta-analysis · 7 studiesCited 8×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →